Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Hepatitis

  Free Subscription


Articles published in J Hepatol

Retrieve available abstracts of 266 articles:
HTML format
Text format



Single Articles


    June 2019
  1. WILSON E, Covert E, Hoffmann J, Comstock E, et al
    A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY).
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307.
    PubMed     Text format     Abstract available


  2. GOTLIEB N, Moradpour D, Shouval D
    Hepatitis A and E - differences and commonalities.
    J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30297.
    PubMed     Text format    


  3. DUSHEIKO G, Lemoine M
    An appraisal of the WHO hepatitis B treatment guidelines applicability to Africans.
    J Hepatol. 2019;70:1046-1048.
    PubMed     Text format    


    May 2019
  4. POL S, Fontaine H, Carrat F
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response.
    J Hepatol. 2019 May 23. pii: S0168-8278(19)30186.
    PubMed     Text format    


  5. VON FELDEN J, Alric L, Pischke S, Aitken C, et al
    The Burden of Hepatitis E among Patients with Hematological Malignancies: a Retrospective European Cohort Study.
    J Hepatol. 2019 May 17. pii: S0168-8278(19)30290.
    PubMed     Text format     Abstract available


  6. EVON DM, Sarkar S, Amador J, Lok AS, et al
    Patient-reported symptoms during and after direct acting antiviral therapies for chronic hepatitis C: The PROP UP Study.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30278.
    PubMed     Text format     Abstract available


  7. JI F, Yeo YH, Wei MT, Ogawa E, et al
    Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: A systematic review and meta-analysis.
    J Hepatol. 2019 May 13. pii: S0168-8278(19)30279.
    PubMed     Text format     Abstract available


  8. ALAVI M, Law MG, Valerio H, Grebely J, et al
    Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    J Hepatol. 2019 May 9. pii: S0168-8278(19)30275.
    PubMed     Text format     Abstract available


  9. KONIG A, Yang J, Jo E, Park KHP, et al
    Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
    J Hepatol. 2019 May 8. pii: S0168-8278(19)30271.
    PubMed     Text format     Abstract available


  10. ANKCORN M, Gallacher J, Ijaz S, Taha Y, et al
    Convalescent Plasma Therapy for Persistent Hepatitis E Virus Infection.
    J Hepatol. 2019 May 7. pii: S0168-8278(19)30269.
    PubMed     Text format    


  11. DIAS J, Hengst J, Parrot T, Leeansyah E, et al
    Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells.
    J Hepatol. 2019 May 6. pii: S0168-8278(19)30270.
    PubMed     Text format     Abstract available


  12. YURDAYDIN C, Abbas Z, Buti M, Cornberg M, et al
    Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
    J Hepatol. 2019;70:1008-1015.
    PubMed     Text format     Abstract available


    April 2019
  13. HONG J, Kushner T, Dieterich D, Garry D, et al
    Reducing mother-to-child transmission of HCV: Is it attainable with a multidisciplinary approach?
    J Hepatol. 2019 Apr 24. pii: S0168-8278(19)30079.
    PubMed     Text format    


  14. SCHULZ M, Papp CP, Bock CT, Hofmann J, et al
    Combination therapy of sofosbuvir and ribavirin fails to clear chronic hepatitis E infection in a multivisceral transplanted patient.
    J Hepatol. 2019 Apr 23. pii: S0168-8278(19)30223.
    PubMed     Text format    


  15. RAIMONDO G, Locarnini S, Pollicino T, Levrero M, et al
    Update of the statements on biology and clinical impact of occult hepatitis b virus infection.
    J Hepatol. 2019 Apr 17. pii: S0168-8278(19)30259.
    PubMed     Text format     Abstract available


  16. WRENSCH F, Keck ZY, Foung SKH, Baumert TF, et al
    Learning from a clinical cohort for HCV vaccine development.
    J Hepatol. 2019 Apr 13. pii: S0168-8278(19)30224.
    PubMed     Text format    


  17. MOUNA L, Rossignol E, Tateo M, Coilly A, et al
    Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference.
    J Hepatol. 2019 Apr 6. pii: S0168-8278(19)30136.
    PubMed     Text format    


  18. CABIBBO G, Celsa C, Calvaruso V, Petta S, et al
    Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30221.
    PubMed     Text format     Abstract available


  19. KIM SU, Seo YS, Lee HA, Kim MN, et al
    A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in the Republic of Korea.
    J Hepatol. 2019 Apr 5. pii: S0168-8278(19)30222.
    PubMed     Text format     Abstract available


  20. UMUTESI G, Shumbusho F, Kateera F, Serumondo J, et al
    Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa.
    J Hepatol. 2019 Apr 1. pii: S0168-8278(19)30179.
    PubMed     Text format    


    March 2019
  21. ABERRA H, Desalegn H, Berhe N, Mekasha B, et al
    The WHO guidelines for chronic hepatitis B fail to detect half of the patients in need of treatment in Ethiopia.
    J Hepatol. 2019 Mar 23. pii: S0168-8278(19)30116.
    PubMed     Text format     Abstract available


  22. WIJAYA RS, Read SA, Schibeci S, Eslam M, et al
    KLRG1+ natural killer cells exert a novel anti-fibrotic function in chronic hepatitis B.
    J Hepatol. 2019 Mar 21. pii: S0168-8278(19)30182.
    PubMed     Text format     Abstract available


  23. DENG L, Jiang W, Wang X, Merz A, et al
    Syntenin regulates Hepatitis C virus sensitivity to neutralizing antibody by promoting E2 secretion through exosomes.
    J Hepatol. 2019 Mar 14. pii: S0168-8278(19)30147.
    PubMed     Text format     Abstract available


  24. LIM YS, Gwak GY, Choi J, Lee YS, et al
    Monotherapy with Tenofovir Disoproxil Fumarate for Adefovir-Resistant vs. Entecavir-Resistant Chronic Hepatitis B: a 5-Year clinical trial.
    J Hepatol. 2019 Mar 12. pii: S0168-8278(19)30142.
    PubMed     Text format     Abstract available


  25. WONG TC, Fung JY, Yu-Shi Cui T, Lam AH, et al
    Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis.
    J Hepatol. 2019 Mar 11. pii: S0168-8278(19)30139.
    PubMed     Text format     Abstract available


  26. FONTAINE H, Alric L, Labreuche J, Legendre B, et al
    Control of replication of hepatitis B and C virus improves patient and graft survival in kidney transplantation.
    J Hepatol. 2019 Mar 9. pii: S0168-8278(19)30020.
    PubMed     Text format     Abstract available


  27. WYLES D, Weiland O, Yao B, Weilert F, et al
    Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.
    J Hepatol. 2019 Mar 8. pii: S0168-8278(19)30078.
    PubMed     Text format    


    February 2019
  28. SAHLI R, Fraga M, Semela D, Moradpour D, et al
    Rabbit HEV in immunosuppressed patients with hepatitis E acquired in Switzerland.
    J Hepatol. 2019 Feb 22. pii: S0168-8278(19)30068.
    PubMed     Text format    


  29. MERAT SJ, Bru C, van de Berg D, Molenkamp R, et al
    Cross-genotype AR3-specific neutralizing antibodies confer long-term protection in injecting drug users after HCV clearance.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30128.
    PubMed     Text format     Abstract available


  30. MORGAN FREIMAN J, Wang J, Easterbrook PJ, Robert Horsburgh C, et al
    Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: analysis of a global dataset.
    J Hepatol. 2019 Feb 20. pii: S0168-8278(19)30125.
    PubMed     Text format     Abstract available


  31. PARK ES, Lee AR, Kim DH, Lee JH, et al
    Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30120.
    PubMed     Text format     Abstract available


  32. DEVARBHAVI H, Asrani SK, Kamath PS
    Reply to: "Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia".
    J Hepatol. 2019 Feb 19. pii: S0168-8278(19)30066.
    PubMed     Text format    


  33. VERGIS N, Atkinson SR, Thursz MR
    The future of therapy for alcoholic hepatitis - Beyond corticosteroids.
    J Hepatol. 2019 Feb 18. pii: S0168-8278(19)30030.
    PubMed     Text format    


  34. SINGH SP, Panigrahi S, Mishra D, Khatua CR, et al
    Alcohol-associated liver disease, not hepatitis B, is the major cause of cirrhosis in Asia.
    J Hepatol. 2019 Feb 16. pii: S0168-8278(19)30012.
    PubMed     Text format    


  35. BANDA DH, Perin PM, Brown RJP, Todt D, et al
    A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30110.
    PubMed     Text format     Abstract available


  36. KEMMING J, Reeves E, Nitschke K, Widmeier V, et al
    ERAP1 allotypes impact the epitope repertoire of virus-specific CD8(+) T cell responses in acute hepatitis C virus infection.
    J Hepatol. 2019 Feb 12. pii: S0168-8278(19)30111.
    PubMed     Text format     Abstract available


  37. IM GY, Cameron AM, Lucey MR
    Liver transplantation for alcoholic hepatitis.
    J Hepatol. 2019;70:328-334.
    PubMed     Text format     Abstract available


  38. MATHURIN P, Thursz M
    Endpoints and patient stratification in clinical trials for alcoholic hepatitis.
    J Hepatol. 2019;70:314-318.
    PubMed     Text format     Abstract available


  39. SINGAL AK, Shah VH
    Current trials and novel therapeutic targets for alcoholic hepatitis.
    J Hepatol. 2019;70:305-313.
    PubMed     Text format     Abstract available


    January 2019
  40. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Text format     Abstract available


  41. PAPALUCA T, McDonald L, Craigie A, Gibson A, et al
    Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
    J Hepatol. 2019 Jan 14. pii: S0168-8278(19)30024.
    PubMed     Text format     Abstract available


  42. HSU YC, Yip TC, Ho HJ, Wong VW, et al
    Corrigendum to "Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B" [J Hepatol 69 (2018) 278-285].
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32629.
    PubMed     Text format    


  43. HSU YC, Yip TC, Wong GL, Wu CY, et al
    Reply to: "Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues".
    J Hepatol. 2019 Jan 8. pii: S0168-8278(18)32583.
    PubMed     Text format    


  44. TSAI JF, Perng DS
    Diabetes mellitus as a risk factor of hepatocellular carcinoma in patients with chronic hepatitis B on nucleot(s)ide analogues.
    J Hepatol. 2019 Jan 7. pii: S0168-8278(18)32546.
    PubMed     Text format    


  45. MARION O, Lhomme S, Del Bello A, Abravanel F, et al
    Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.
    J Hepatol. 2019;70:206-209.
    PubMed     Text format    


    December 2018
  46. DENOLLY S, Granier C, Fontaine N, Pozzetto B, et al
    A serum protein factor mediates maturation and apoB-association of HCV particles in the extracellular milieu.
    J Hepatol. 2018 Dec 13. pii: S0168-8278(18)32619.
    PubMed     Text format     Abstract available


  47. BARBARA T, Fanny L, Caroline S, Francoise B, et al
    Serum Hepatitis B core-related antigen (HBcrAg) correlates with covalently-closed circular DNA transcriptional activity in chronic hepatitis B patients.
    J Hepatol. 2018 Dec 6. pii: S0168-8278(18)32582.
    PubMed     Text format     Abstract available


  48. BOEREKAMPS A, Vanwolleghem T, van der Valk M, van den Berk GE, et al
    8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study).
    J Hepatol. 2018 Dec 5. pii: S0168-8278(18)32516.
    PubMed     Text format    


  49. DE MARTIN E, Michot JM, Papouin B, Champiat S, et al
    Reply to: "Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?"
    J Hepatol. 2018 Dec 4. pii: S0168-8278(18)32548.
    PubMed     Text format    


    November 2018
  50. RIVEIRO-BARCIELA M, Munoz-Couselo E, Fernandez-Sojo J, Diaz-Mejia N, et al
    Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: New settings call for new treatment strategies?
    J Hepatol. 2018 Nov 28. pii: S0168-8278(18)32504.
    PubMed     Text format    


  51. MODIN L, Arshad A, Wilkes B, Benselin J, et al
    Epidemiology and natural history of hepatitis C virus infection among children and young people.
    J Hepatol. 2018 Nov 26. pii: S0168-8278(18)32545.
    PubMed     Text format     Abstract available


  52. VAN SEYEN M, Smolders EJ, van Wijngaarden P, Drenth JPH, et al
    Successful HCV treatment of patients on contraindicated anti-epileptic drugs: Role of drug level monitoring.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32492.
    PubMed     Text format    


  53. D'AMBROSIO R, Pasulo L, Puoti M, Vinci M, et al
    Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in 723 patients with chronic hepatitis C.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32543.
    PubMed     Text format     Abstract available


  54. RASCHE A, Sander AL, Corman VM, Drexler JF, et al
    Evolutionary biology of human hepatitis viruses.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32542.
    PubMed     Text format     Abstract available


  55. COSTA R, Todt D, Zapatero-Belinchon F, Schenk C, et al
    SEC14L2, a lipid-binding protein, regulate HCV replication in culture with inter- and intra- genotype variations.
    J Hepatol. 2018 Nov 22. pii: S0168-8278(18)32544.
    PubMed     Text format     Abstract available


  56. PHILIPS CA, Augustine P, Padsalgi G, Ahamed R, et al
    Only in the darkness can you see the stars: Severe alcoholic hepatitis and higher grades of acute-on-chronic liver failure.
    J Hepatol. 2018 Nov 20. pii: S0168-8278(18)32456.
    PubMed     Text format    


  57. TRIVEDI PJ, Hubscher SG, Heneghan M, Gleeson D, et al
    Grand Round: Autoimmune Hepatitis.
    J Hepatol. 2018 Nov 19. pii: S0168-8278(18)32538.
    PubMed     Text format     Abstract available


  58. STAMM LM, Brainard DM, McHutchison JG
    Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Nov 13. pii: S0168-8278(18)32528.
    PubMed     Text format    


  59. KHERA T, Behrendt P, Bankwitz D, Brown RJP, et al
    Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32527.
    PubMed     Text format     Abstract available



  60. Reply to: "Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: Response to EASL Recommendations on Treatment of Hepatitis C 2018".
    J Hepatol. 2018 Nov 12. pii: S0168-8278(18)32529.
    PubMed     Text format    


  61. PHAM LV, Jensen SB, Fahnoe U, Pedersen MS, et al
    HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.
    J Hepatol. 2018 Nov 2. pii: S0168-8278(18)32515.
    PubMed     Text format     Abstract available


    October 2018
  62. JENNY I, Gregory JD, Beth C, Philip C, et al
    Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    J Hepatol. 2018 Oct 24. pii: S0168-8278(18)32494.
    PubMed     Text format     Abstract available


  63. IOANNOU GN
    Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment".
    J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445.
    PubMed     Text format    


  64. SCHUCH A, Zecher BF, Muller PA, Correia MP, et al
    NK-cell responses are biased towards CD16-mediated effector functions in chronic Hepatitis B virus infection.
    J Hepatol. 2018 Oct 17. pii: S0168-8278(18)32458.
    PubMed     Text format     Abstract available


  65. JI F, Yeo YH, He C, Li J, et al
    Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32390.
    PubMed     Text format    


  66. NISHIBATAKE KINOSHITA M, Minami T, Tateishi R, Wake T, et al
    Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy.
    J Hepatol. 2018 Oct 15. pii: S0168-8278(18)32454.
    PubMed     Text format     Abstract available


  67. NEWSUM AM, Molenkamp R, van der Meer JT, Rebers SP, et al
    Persistence of NS5B-S282T, a sofosbuvir resistance-associated substitution, in a HIV/HCV-coinfected MSM with risk of onward transmission.
    J Hepatol. 2018;69:968-970.
    PubMed     Text format    


  68. BERENGUER M, de la Rosa Rodriguez G, Dominguez-Gil B
    Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain.
    J Hepatol. 2018;69:966-968.
    PubMed     Text format    


  69. DEUFFIC-BURBAN S, Huneau A, Verleene A, Brouard C, et al
    Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    J Hepatol. 2018;69:785-792.
    PubMed     Text format     Abstract available


  70. NGUYEN MH, Ozbay AB, Liou I, Meyer N, et al
    Healthcare Resource Utilization and Costs by Disease Severity in an Insured National Sample of US Patients with Chronic Hepatitis B.
    J Hepatol. 2018 Oct 1. pii: S0168-8278(18)32440.
    PubMed     Text format     Abstract available


    September 2018
  71. BELPERIO PS, Shahoumian TA, Loomis TP, Mole LA, et al
    Real-world Effectiveness of Daclatasvir plus Sofosbuvir and Velpatasvir/Sofosbuvir in Hepatitis C Genotype 2 and 3.
    J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32392.
    PubMed     Text format     Abstract available


    August 2018
  72. ALY MOKHLES M
    Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land.
    J Hepatol. 2018 Aug 31. pii: S0168-8278(18)32270.
    PubMed     Text format    


  73. ZHAO P
    Reply to: "Antiviral therapy in hepatitis B virus-infected immunotolerant children, exploring a new land".
    J Hepatol. 2018 Aug 30. pii: S0168-8278(18)32299.
    PubMed     Text format    


  74. SERSTE T, Moreno C, Gustot T
    Reply to: "Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis".
    J Hepatol. 2018 Aug 29. pii: S0168-8278(18)32277.
    PubMed     Text format    


  75. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Prevalent acute-on-chronic liver failure and response to corticosteroids in alcoholic hepatitis.
    J Hepatol. 2018 Aug 24. pii: S0168-8278(18)32172.
    PubMed     Text format    


  76. ROSSI C, Butt Z, Wong S, Buxton J, et al
    Hepatitis C Virus Reinfection after Successful Treatment with Direct-Acting Antiviral Therapy in a Large Population-Based Cohort.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32288.
    PubMed     Text format     Abstract available


  77. KO C, Chakraborty A, Chou WM, Hasreiter J, et al
    Hepatitis B virus (HBV) genome recycling and de novo secondary infection events maintain stable cccDNA levels.
    J Hepatol. 2018 Aug 21. pii: S0168-8278(18)32294.
    PubMed     Text format     Abstract available


  78. FONTANA RJ, Cirulli ET, Gu J, Kleiner D, et al
    The role of HLA-A *33:01 in Patients with Cholestatic Hepatitis attributed to Terbinafine.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32283.
    PubMed     Text format     Abstract available


  79. IOANNOU GN, Green PK, Beste LA, Mun EJ, et al
    Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C.
    J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287.
    PubMed     Text format     Abstract available


  80. TERRAULT NA, Pageaux GP
    A changing landscape of liver transplantation: King HCV is dethroned, ALD and NAFLD take over!
    J Hepatol. 2018 Aug 10. pii: S0168-8278(18)32276.
    PubMed     Text format    


  81. SARRAZIN C, Cooper CL, Manns MP, Reddy KR, et al
    No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients.
    J Hepatol. 2018 Aug 8. pii: S0168-8278(18)32279.
    PubMed     Text format     Abstract available


  82. DE MARTIN E, Michot JM, Papouin B, Champiat S, et al
    Reply to: "Mortality due to immunotherapy related hepatitis".
    J Hepatol. 2018 Aug 7. pii: S0168-8278(18)32261.
    PubMed     Text format    


  83. BHAVE P, Buckle A, Sandhu S, Sood S, et al
    Mortality due to immunotherapy related hepatitis.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32165.
    PubMed     Text format    


  84. LAL BB, Sood V, Khanna R, Alam S, et al
    Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32173.
    PubMed     Text format    


  85. HERZER K, Gerken G, Kroy D, Tacke F, et al
    Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany.
    J Hepatol. 2018 Aug 6. pii: S0168-8278(18)32179.
    PubMed     Text format    


  86. ZHU S, Zhao P
    Reply to: "Immunotolerant children with chronic hepatitis B - To treat or not - The dilemma continues".
    J Hepatol. 2018 Aug 4. pii: S0168-8278(18)32265.
    PubMed     Text format    


    July 2018
  87. KIM JH, Kim YD, Lee M, Jun BG, et al
    Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy.
    J Hepatol. 2018 Jul 31. pii: S0168-8278(18)32274.
    PubMed     Text format     Abstract available


  88. LAZARUS JV, Pericas JM, Colombo M, Ninburg M, et al
    Viral hepatitis: "E" is for equitable elimination.
    J Hepatol. 2018 Jul 20. pii: S0168-8278(18)32171.
    PubMed     Text format    


  89. MCMAHON BJ, Dusheiko G
    Predicting treatment eligibility for hepatitis B in low income regions: Can treatment scores without HBV DNA testing serve the purpose?
    J Hepatol. 2018 Jul 11. pii: S0168-8278(18)32126.
    PubMed     Text format    


  90. VERMEHREN J, Park JS, Jacobson I, Zeuzem S, et al
    Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection.
    J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181.
    PubMed     Text format     Abstract available


  91. GRAUPERA I, Lammert F
    Screening is caring: Community-based non-invasive diagnosis and treatment strategies for hepatitis C to reduce liver disease burden.
    J Hepatol. 2018 Jul 5. pii: S0168-8278(18)32125.
    PubMed     Text format    


    June 2018
  92. MARSHALL AD, Pawlotsky JM, Lazarus JV, Aghemo A, et al
    The removal of DAA restrictions in Europe - one step closer to eliminating HCV as a major public health threat.
    J Hepatol. 2018 Jun 27. pii: S0168-8278(18)32169.
    PubMed     Text format     Abstract available


  93. ROCA SUAREZ AA, Baumert TF, Lupberger J
    Beyond viral dependence: The pathological consequences of HCV-induced EGF signaling.
    J Hepatol. 2018 Jun 21. pii: S0168-8278(18)32118.
    PubMed     Text format    


  94. SZABO G
    More than meets the eye: Severe alcoholic hepatitis can present as acute-on-chronic liver failure.
    J Hepatol. 2018 Jun 20. pii: S0168-8278(18)32116.
    PubMed     Text format    


  95. FORNS X, Sarrazin C
    Treatment of chronic hepatitis C.
    J Hepatol. 2018 Jun 8. pii: S0168-8278(18)32019.
    PubMed     Text format    


  96. AGARWAL K, Castells L, Mullhaupt B, Rosenberg WMC, et al
    Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients.
    J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32124.
    PubMed     Text format     Abstract available


  97. GRONBAEK L, Vilstrup H, Pedersen L, Christensen K, et al
    Family occurrence of autoimmune hepatitis: A Danish nationwide registry-based cohort study.
    J Hepatol. 2018 Jun 6. pii: S0168-8278(18)32120.
    PubMed     Text format     Abstract available


  98. VAN EIJK JJJ, Cintas P, Jacobs BC, Kamar N, et al
    Reply to: "Association of hepatitis E virus infection and myasthenia gravis: A pilot study".
    J Hepatol. 2018;68:1321-1322.
    PubMed     Text format    


    May 2018
  99. OJHA RP, Steyerberg EW
    Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?
    J Hepatol. 2018 May 26. pii: S0168-8278(18)31980.
    PubMed     Text format    


  100. CHEVALIEZ S, Pawlotsky JM
    New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.
    J Hepatol. 2018 May 22. pii: S0168-8278(18)32063.
    PubMed     Text format     Abstract available


  101. PEERAPHATDIT TB, Simonetto DA, Shah VH
    Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.
    J Hepatol. 2018 May 21. pii: S0168-8278(18)32058.
    PubMed     Text format    


  102. DE MARTIN E, Michot JM, Champiat S, Lambotte O, et al
    Reply to: "Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?"
    J Hepatol. 2018 May 15. pii: S0168-8278(18)32030.
    PubMed     Text format    


  103. WONG GL, Chan HL, Tse YK, Yip TC, et al
    Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32055.
    PubMed     Text format     Abstract available


  104. RINKER F, Zimmer CL, Siederdissen CHZ, Manns MP, et al
    Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32050.
    PubMed     Text format     Abstract available


  105. BUGGISCH P, Zeuzem S
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2018 May 11. pii: S0168-8278(18)32051.
    PubMed     Text format     Abstract available


  106. SINGAL AK, Louvet A, Shah VH, Kamath PS, et al
    Grand Rounds: Alcoholic Hepatitis.
    J Hepatol. 2018 May 10. pii: S0168-8278(18)32047.
    PubMed     Text format     Abstract available


  107. GAUCI ML, Baroudjian B, Zeboulon C, Pages C, et al
    Immune-related hepatitis with immunotherapy: Are corticosteroids always needed?
    J Hepatol. 2018 May 7. pii: S0168-8278(18)32025.
    PubMed     Text format    


    April 2018
  108. BLOOM S, Kemp W, Nicoll A, Roberts SK, et al
    Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C.
    J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023.
    PubMed     Text format     Abstract available


  109. MULLHAUPT B, Niederhauser C
    Hepatitis E blood donor screening - More than a mere drop in the ocean?
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32015.
    PubMed     Text format    


  110. GROEPPER C, Rufinatscha K, Schroder N, Stindt S, et al
    HCV modifies EGF signalling and upregulates production of CXCR2 ligands: role in inflammation and antiviral immune response.
    J Hepatol. 2018 Apr 26. pii: S0168-8278(18)32013.
    PubMed     Text format     Abstract available


  111. WANG L, Gao F, Lin G, Yuan Y, et al
    Association of hepatitis E virus infection and myasthenia gravis: A pilot study.
    J Hepatol. 2018 Apr 19. pii: S0168-8278(18)30133.
    PubMed     Text format    


  112. SUSLOV A, Heim MH, Wieland S
    New insights into hepatitis D virus (HDV) induced innate immunity: MDA5 senses HDV replication.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31972.
    PubMed     Text format    


  113. BRANDL K, Hartmann P, Jih LJ, Pizzo DP, et al
    Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis.
    J Hepatol. 2018 Apr 11. pii: S0168-8278(18)31973.
    PubMed     Text format     Abstract available



  114. EASL Recommendations on Treatment of Hepatitis C 2018.
    J Hepatol. 2018 Apr 9. pii: S0168-8278(18)31968.
    PubMed     Text format    


  115. ABDEL-MONEIM A, Aboud A, Abdel-Gabbar M, Zanaty MI, et al
    A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure.
    J Hepatol. 2018 Apr 3. pii: S0168-8278(18)30174.
    PubMed     Text format    


  116. AGARWAL K, Brunetto M, Seto WK, Lim YS, et al
    96weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
    J Hepatol. 2018;68:672-681.
    PubMed     Text format     Abstract available


  117. ALAZAWI W, Knolle PA
    Interfering with Kupffer cell replenishment: New insights into liver injury.
    J Hepatol. 2018;68:635-637.
    PubMed     Text format    


  118. MEFFERT PJ, Repp KD, Volzke H, Weiss FU, et al
    The PNPLA3 SNP rs738409:G allele is associated with increased liver disease-associated mortality but reduced overall mortality in a population-based cohort.
    J Hepatol. 2018;68:858-860.
    PubMed     Text format    


  119. NAKAO Y, Hashimoto S, Abiru S, Komori A, et al
    Rapidly growing, moderately differentiated HCC: A clinicopathological characteristic of HCC occurrence after IFN-free DAA therapy?
    J Hepatol. 2018;68:854-855.
    PubMed     Text format    


  120. WANG J, Yu Y, Meng Z, Shen C, et al
    Reply to: "HBV RNA virion-like particles produced under nucleos(t)ide analogues treatment are mainly replication-deficient".
    J Hepatol. 2018;68:849-851.
    PubMed     Text format    


    March 2018

  121. EASL Clinical Practice Guidelines on hepatitis E virus infection.
    J Hepatol. 2018 Mar 30. pii: S0168-8278(18)30155.
    PubMed     Text format     Abstract available


  122. HSU YC, Cheuk-Fung Yip T, Ho HJ, Wai-Sun Wong V, et al
    Development of a scoring system to Predict Hepatocellular Carcinoma in Asians on Antivirals for Chronic Hepatitis B.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30170.
    PubMed     Text format     Abstract available


  123. ROMANO A, Angeli P, Piovesan S, Noventa F, et al
    "Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study".
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172.
    PubMed     Text format     Abstract available


  124. PUOTI M, Foster GR, Wang S, Mutimer D, et al
    High SVR12 with 8-week and 12-week Glecaprevir/Pibrentasvir: Integrated Analysis of HCV Genotype 1-6 Patients Without Cirrhosis.
    J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30165.
    PubMed     Text format     Abstract available


  125. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode (Reply).
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30145.
    PubMed     Text format    


  126. ZHANG Z, Filzmayer C, Ni Y, Sultmann H, et al
    Hepatitis D Virus replication is sensed by MDA5 and induces IFN-beta/lambda responses in hepatocytes.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30143.
    PubMed     Text format     Abstract available


  127. SANDAHL TD, Vilstrup H, Jepsen P
    The long-term prognosis of Alcoholic Hepatitis is poor and independent of disease severity for patients surviving an acute episode.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30147.
    PubMed     Text format    


  128. SERSTE T, Cornillie A, Njimi H, Pavesi M, et al
    The prognostic value of Acute-on-Chronic Liver Failure during the course of severe alcoholic hepatitis.
    J Hepatol. 2018 Mar 7. pii: S0168-8278(18)30144.
    PubMed     Text format     Abstract available


  129. LUTHER J, Dienstag JL
    Reply: Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30141.
    PubMed     Text format    


  130. DELTENRE P, Marot A, Dubois M, Trepo E, et al
    Assessment of the risk of alcohol relapse following liver transplantation for alcoholic hepatitis using a meta-analysis approach.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30142.
    PubMed     Text format    


  131. PETTA S, Adinolfi LE, Fracanzani AL, Rini F, et al
    Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis.
    J Hepatol. 2018 Mar 2. pii: S0168-8278(18)30132.
    PubMed     Text format     Abstract available


  132. TOYODA H, Kumada T, Tada T, Mizuno K, et al
    Imaging basis of AFP and WFA(+)M2BP as indicators of the risk of HCC after SVR.
    J Hepatol. 2018;68:606-607.
    PubMed     Text format    


  133. CAMMA C, Leandro G
    Direct antiviral agents and risk of HCC: Waiting for Godot.
    J Hepatol. 2018;68:614-616.
    PubMed     Text format    


    February 2018
  134. CRESPO G, Trota N, Londono MC, Mauro E, et al
    The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in wait-list composition.
    J Hepatol. 2018 Feb 23. pii: S0168-8278(18)30129.
    PubMed     Text format     Abstract available


  135. ZHU S, Zhang H, Dong Y, Wang L, et al
    Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characters: a pilot open-lable randomized study.
    J Hepatol. 2018 Feb 13. pii: S0168-8278(18)30117.
    PubMed     Text format     Abstract available


  136. DE CARVALHO DOMINGUEZ SOUZA BF, Konig A, Rasche A, de Oliveira Carneiro I, et al
    A novel hepatitis B virus species discovered in capuchin monkeys sheds new light on the evolution of primate hepadnaviruses.
    J Hepatol. 2018 Feb 8. pii: S0168-8278(18)30079.
    PubMed     Text format     Abstract available


  137. PAPATHEODORIDIS GV, Sypsa V, Dalekos G, Yurdaydin C, et al
    8-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
    J Hepatol. 2018 Feb 7. pii: S0168-8278(18)30081.
    PubMed     Text format     Abstract available


    January 2018
  138. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2018 Jan 31. pii: S0168-8278(18)30064.
    PubMed     Text format    


  139. LEMOINE M, Cooke GS
    The Egyptian hepatitis C programme: a model of HCV treatment intervention?
    J Hepatol. 2018 Jan 30. pii: S0168-8278(18)30068.
    PubMed     Text format    


  140. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Corrigendum to "Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV" [J Hepatol 68 (2018) 33-41].
    J Hepatol. 2018 Jan 20. pii: S0168-8278(18)30013.
    PubMed     Text format    


  141. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Reply to: No effect of resistance-associated substitutions in patients with rare HCV subtypes following treatment with sofosbuvir-containing regimens.
    J Hepatol. 2018 Jan 12. pii: S0168-8278(18)30014.
    PubMed     Text format    


    December 2017
  142. SCHWARZINGER M, Rehm J, Mallet V
    "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 30. pii: S0168-8278(17)32539.
    PubMed     Text format    


  143. ALAVI M, Law MG, Dore GJ
    Reply to: "Who killed JR": chronic hepatitis C or alcohol use disorders?
    J Hepatol. 2017 Dec 29. pii: S0168-8278(17)32538.
    PubMed     Text format    


  144. AMPUERO J, Jimeno C, Quiles R, Rosales JM, et al
    Impact of comorbidities on patients outcomes after interferon-free therapy-induced viral eradication in hepatitis.
    J Hepatol. 2017 Dec 27. pii: S0168-8278(17)32535.
    PubMed     Text format     Abstract available


  145. SCOTT N, Olafsson S, Gottfreethsson M, Tyrfingsson T, et al
    Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
    J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32528.
    PubMed     Text format     Abstract available


  146. SODERHOLM J, Millbourn C, Busch K, Kovamees J, et al
    Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32485.
    PubMed     Text format     Abstract available


  147. HELLARD M, Scott N, Sacks Davis R, Pedrana A, et al
    Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
    J Hepatol. 2017 Dec 9. pii: S0168-8278(17)32486.
    PubMed     Text format    


  148. ASSELAH T, Hassanein T, Waked I, Mansouri A, et al
    Eliminating Hepatitis C within Low Income Countries - the need to cure Genotypes 4, 5, 6.
    J Hepatol. 2017 Dec 8. pii: S0168-8278(17)32482.
    PubMed     Text format     Abstract available


  149. ELSHARKAWY A, Raziky ME, Akel WE, Saeed KE, et al
    Planning and prioritizing direct acting antivirals treatment for HCV patients in countries with limited resources: lessons from the Egyptian experience.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32478.
    PubMed     Text format     Abstract available


  150. OVREHUS ALH, Krarup H, Birkemose I, Holm DK, et al
    Four weeks of ledipasvir/sofosbuvir and ribavirin with or without pegylated interferon for chronic hepatitis C in non-cirrhotic people who inject drugs. A randomized trial.
    J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32475.
    PubMed     Text format    


  151. HEZODE C, Reau N, Svarovskaia ES, Doehle BP, et al
    Resistance Analysis in Patients with Genotype 1-6 HCV Infection Treated with Sofosbuvir/Velpatasvir in the Phase 3 Studies.
    J Hepatol. 2017 Dec 5. pii: S0168-8278(17)32476.
    PubMed     Text format     Abstract available


  152. ZOULIM F
    Inhibition of hepatitis B virus gene expression: a step towards functional cure.
    J Hepatol. 2017 Dec 4. pii: S0168-8278(17)32480.
    PubMed     Text format    


  153. BORST K, Frenz T, Spanier J, Tegtmeyer PK, et al
    Type I interferon receptor-signaling delays Kupffer cell replenishment during acute fulminant viral hepatitis.
    J Hepatol. 2017 Dec 2. pii: S0168-8278(17)32473.
    PubMed     Text format     Abstract available


    November 2017
  154. HARTL J, Ehlken H, Sebode M, Peiseler M, et al
    Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis.
    J Hepatol. 2017 Nov 24. pii: S0168-8278(17)32445.
    PubMed     Text format     Abstract available


  155. KUBILIUN M, Patel SJ, Hur C, Dienstag JL, et al
    Early liver transplantation for alcoholic hepatitis: Ready for primetime?
    J Hepatol. 2017 Nov 23. pii: S0168-8278(17)32452.
    PubMed     Text format    


  156. HUPA KL, Deterding K, Port K, Kimmann M, et al
    In Reply to: EASL RECOMMENDATIONS ON TREATMENT OF HEPATITIS C 2016 "Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C?"
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32443.
    PubMed     Text format    


  157. FORREST EH, Atkinson SR, Richardson P, Masson S, et al
    Application of Prognostic Scores in The Stopah Trial: Discriminant Function is no Longer the Optimal Scoring System in Alcoholic Hepatitis.
    J Hepatol. 2017 Nov 21. pii: S0168-8278(17)32440.
    PubMed     Text format     Abstract available


  158. INNES H, Barclay ST, Hayes PC, Fraser A, et al
    The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen.
    J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429.
    PubMed     Text format     Abstract available


  159. TANG Y, Li H, Li J, Liu Y, et al
    Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil mediated complement activation.
    J Hepatol. 2017 Nov 14. pii: S0168-8278(17)32433.
    PubMed     Text format     Abstract available


  160. BUGGISCH P, Vermehren J, Mauss S, Gunther R, et al
    Real-world effectiveness of 8 weeks treatment with ledipasvir/sofosbuvir in chronic hepatitis C.
    J Hepatol. 2017 Nov 10. pii: S0168-8278(17)32431.
    PubMed     Text format     Abstract available


  161. OSSEMAN Q, Gallucci L, Au S, Cazenave C, et al
    The chaperone dynein LL1 mediates cytoplasmic transport of empty and mature hepatitis B virus capsids.
    J Hepatol. 2017 Nov 4. pii: S0168-8278(17)32424.
    PubMed     Text format     Abstract available


  162. CARRIERI MP, Protopopescu C, Marcellin F, Wittkop L, et al
    The impact of coffee consumption on fibrosis and steatosis in HIV-HCV co-infected patients.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32406.
    PubMed     Text format    


  163. JANSSEN HLA, Brunetto MR, Kim YJ, Ferrari C, et al
    Safety, Efficacy and Pharmacodynamics of Vesatolimod (GS-9620) in Virally-Suppressed Patients with Chronic Hepatitis B.
    J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32408.
    PubMed     Text format     Abstract available


    October 2017
  164. MURCIA O, Carnicer F, Gomez-Escolar L, Miralles C, et al
    Direct antiviral agents against Hepatitis C virus: beneficial or harmful?
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32407.
    PubMed     Text format    


  165. POLLMANN J, Gotz JJ, Rupp D, Strauss O, et al
    Hepatitis C virus-induced natural killer cell proliferation involves monocyte-derived cells and the OX40/OX40L axis.
    J Hepatol. 2017 Oct 31. pii: S0168-8278(17)32400.
    PubMed     Text format     Abstract available


  166. ALAVI M, Janjua NZ, Chong M, Grebely J, et al
    The contribution of alcohol-use disorder to decompensated cirrhosis among people with hepatitis C: an international study.
    J Hepatol. 2017 Oct 26. pii: S0168-8278(17)32398.
    PubMed     Text format     Abstract available


  167. LONDONO MC, Forns X, Pascasio JM
    Reply to: "Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32385.
    PubMed     Text format    


  168. FRASER H, Martin NK, Brummer-Korvenkontio H, Carrieri P, et al
    Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe".
    J Hepatol. 2017 Oct 25. pii: S0168-8278(17)32387.
    PubMed     Text format     Abstract available


  169. AZAB M, Shah S, Liu X, Ukken J, et al
    Extended DAA indications for hepatitis C patients awaiting liver transplantation and further statistical considerations.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32390.
    PubMed     Text format    


  170. MUELLER H, Wildum S, Luangsay S, Walther J, et al
    A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression.
    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393.
    PubMed     Text format     Abstract available


  171. BERG T, Petersen J
    Predicting long-term response after stopping nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B.
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32345.
    PubMed     Text format    


  172. YU Y, Wang J, Li G, Shen C, et al
    Nucleos(t)ide analogue interruption: Alternative approach to intrahepatic set point for spontaneous control of HBV replication?
    J Hepatol. 2017 Oct 6. pii: S0168-8278(17)32346.
    PubMed     Text format    


  173. YIP TC, Wong GL, Wong VW, Tse YK, et al
    Durability of Hepatitis B Surface Antigen Seroclearance in Untreated and Nucleos(t)ide Analogue-Treated Patients.
    J Hepatol. 2017 Oct 5. pii: S0168-8278(17)32332.
    PubMed     Text format     Abstract available


  174. HALFON P, Scholtes C, Izopet J, Larrat S, et al
    Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world.
    J Hepatol. 2017 Oct 4. pii: S0168-8278(17)32333.
    PubMed     Text format     Abstract available


    September 2017
  175. LIEBER SR, Rice JP, Lucey MR, Bataller R, et al
    Controversies in Clinical Trials for Alcoholic Hepatitis.
    J Hepatol. 2017 Sep 28. pii: S0168-8278(17)32325.
    PubMed     Text format     Abstract available


  176. DI MAIO VC, Cento V, Aragri M, Paolucci S, et al
    Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: what are the chances for second-line regimens?
    J Hepatol. 2017 Sep 20. pii: S0168-8278(17)32288.
    PubMed     Text format    


  177. LIU X, Shen JJ, Jung Kim S, Lee YJ, et al
    Necessity of time series analysis and effects of direct-acting antivirals on HCV patients awaiting liver transplantation.
    J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32290.
    PubMed     Text format    


  178. ESMAT G, Elbaz T, El Raziky M, Gomaa A, et al
    Effectiveness of ravidasvir plus sofosbuvir in interferon-naive and treated patients with chronic hepatitis c genotype-4.
    J Hepatol. 2017 Sep 18. pii: S0168-8278(17)32286.
    PubMed     Text format     Abstract available


  179. PRENNER S, Kulik L
    Reply to "Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma".
    J Hepatol. 2017 Sep 13. pii: S0168-8278(17)32283.
    PubMed     Text format    


  180. CARRIERI MP, Protopopescu C, Marcellin F, Rosellini S, et al
    Protective effect of coffee consumption on all-cause mortality of French HIV-HCV co-infected patients.
    J Hepatol. 2017 Sep 12. pii: S0168-8278(17)32211.
    PubMed     Text format     Abstract available


  181. FANGAZIO S, Camatta D, Minh MT, Ceriani E, et al
    Treatment failure after interferon-free treatment of hepatitis C as a clue of a yet undetected hepatocellular carcinoma.
    J Hepatol. 2017 Sep 7. pii: S0168-8278(17)32280.
    PubMed     Text format    


  182. IOANNOU GN, Green PK, Berry K
    HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273.
    PubMed     Text format     Abstract available


  183. KO HL, Lam TH, Ng H, Toh J, et al
    Identification of Slug and Sox7 as transcriptional repressors binding to the Hepatitis B Virus Core Promoter.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32276.
    PubMed     Text format     Abstract available


  184. QI X, Liu F, Li Z, Chen S, et al
    Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32277.
    PubMed     Text format    


  185. LEMON SM, Ott JJ, Van Damme P, Shouval D, et al
    Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention.
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32278.
    PubMed     Text format     Abstract available


  186. IRANMANESH P, Toso C
    Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis".
    J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32274.
    PubMed     Text format    


  187. KARAMPATOU A, Han X, Kondili LA, Taliani G, et al
    Premature ovarian senescence and high miscarriage rate impair fertility in women with hepatitis C virus infection.
    J Hepatol. 2017 Sep 4. pii: S0168-8278(17)32259.
    PubMed     Text format     Abstract available


  188. HUANG R, Liu Y, Wang J, Xia J, et al
    Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32270.
    PubMed     Text format    


  189. YIP TC, Chan HL, Wong VW, Wong GL, et al
    Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance".
    J Hepatol. 2017 Sep 1. pii: S0168-8278(17)32266.
    PubMed     Text format    


    August 2017
  190. CALVARUSO V, Craxi A
    HBV recurrence after HCV clearance on DAAs: Sometimes They Come Back.
    J Hepatol. 2017 Aug 29. pii: S0168-8278(17)32256.
    PubMed     Text format    


  191. MALLET V, Bruneau J, Zuber J, Alanio C, et al
    Hepatitis E Virus-Induced Primary Cutaneous CD30(+) T cell Lymphoproliferative Disorder.
    J Hepatol. 2017 Aug 28. pii: S0168-8278(17)32250.
    PubMed     Text format     Abstract available


  192. KRAMER L, Laurain A, Sultanik P, Tremeaux P, et al
    "Empirical" retreatment of patients with chronic hepatitis C who failed a first direct-acting antiviral-based regimen.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32251.
    PubMed     Text format    


  193. GARVEY P, Murphy N, Flanagan P, Brennan A, et al
    Disease Outcomes in a Cohort of Women Infected by Hepatitis C-Contaminated anti-D Immunoglobulin During 1970s.
    J Hepatol. 2017 Aug 23. pii: S0168-8278(17)32249.
    PubMed     Text format     Abstract available


  194. PASCASIO JM, Vinaixa C, Ferrer MT, Colmenero J, et al
    Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.
    J Hepatol. 2017 Aug 22. pii: S0168-8278(17)32215.
    PubMed     Text format     Abstract available


  195. MELE D, Mantovani S, Oliviero B, Grossi G, et al
    Monocytes inhibit hepatitis C virus-induced TRAIL expression on CD56bright NK cells.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32203.
    PubMed     Text format     Abstract available


  196. DONATO MF, Invernizzi F, Rossi G, Iavarone M, et al
    Interferon-free therapy of hepatitis C during wait list and post-transplant risk of hepatocellular carcinoma recurrence.
    J Hepatol. 2017 Aug 10. pii: S0168-8278(17)32200.
    PubMed     Text format    


  197. WAZIRY R, Hajarizadeh B, Grebely J, Amin J, et al
    Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression.
    J Hepatol. 2017 Aug 9. pii: S0168-8278(17)32199.
    PubMed     Text format     Abstract available


  198. DONG YANG J, Leise MD
    Reply to " Interferon-free therapy of hepatitis C during wait list and post transplant risk of hepatocellular carcinoma recurrence".
    J Hepatol. 2017 Aug 8. pii: S0168-8278(17)32201.
    PubMed     Text format    


  199. ZEUZEM S, Dvory-Sobol H, Brainard DM
    No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32191.
    PubMed     Text format    


  200. DA SILVA FILIPE A, Sreenu V, Hughes J, Aranday-Cortes E, et al
    Response to DAA Therapy in the NHS England Early Access Programme for Rare HCV Subtypes from Low and Middle Income Countries.
    J Hepatol. 2017 Aug 5. pii: S0168-8278(17)32195.
    PubMed     Text format    


    July 2017
  201. LAZARUS JV, Wiktor S, Colombo M, Thursz M, et al
    Micro-elimination - A path to global elimination of hepatitis C.
    J Hepatol. 2017 Jul 28. pii: S0168-8278(17)32141.
    PubMed     Text format    


  202. SUDA T, Shimakami T, Shirasaki T, Yamashita T, et al
    Reactivation of Hepatitis B Virus from an isolated Anti-HBc positive patient after eradication of Hepatitis C Virus with Direct-acting Antiviral Agents.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32158.
    PubMed     Text format    


  203. LOK AS, Zoulim F, Dusheiko G, Ghany MG, et al
    Hepatitis B cure: From discovery to regulatory approval.
    J Hepatol. 2017 Jul 21. pii: S0168-8278(17)32017.
    PubMed     Text format     Abstract available


  204. RAJORIYA N, Combet C, Zoulim F, Janssen HLA, et al
    How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualized approach?
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32154.
    PubMed     Text format     Abstract available


  205. BERG T, Simon KG, Mauss S, Schott E, et al
    Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study.
    J Hepatol. 2017 Jul 20. pii: S0168-8278(17)32155.
    PubMed     Text format     Abstract available


  206. DALTON HR, van Eijk JJJ, Cintas P, Madden RG, et al
    Hepatitis E Virus Infection and Acute Non-Traumatic Neurological Injury: A Prospective Multicentre Study.
    J Hepatol. 2017 Jul 19. pii: S0168-8278(17)32153.
    PubMed     Text format     Abstract available


  207. KOLLY P, Waidmann O, Vermehren J, Moreno C, et al
    Hepatocellular Carcinoma Recurrence after Direct Antiviral Agent Treatment: a European Multicentre Study.
    J Hepatol. 2017 Jul 18. pii: S0168-8278(17)32150.
    PubMed     Text format    


  208. SAMJI H, Yu A, Kuo M, Alavi M, et al
    Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development.
    J Hepatol. 2017 Jul 3. pii: S0168-8278(17)32133.
    PubMed     Text format     Abstract available


    June 2017

  209. Response to the Cochrane Systematic Review on DAA-Based Treatment of Chronic Hepatitis C.
    J Hepatol. 2017 Jun 29. pii: S0168-8278(17)32129.
    PubMed     Text format    


  210. YIP TC, Chan HL, Wong VW, Tse YK, et al
    Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2017 Jun 23. pii: S0168-8278(17)32092.
    PubMed     Text format     Abstract available


  211. XIANG X, You XM, Zhong JH, Li LQ, et al
    Hepatocellular carcinoma in the absence of cirrhosis in patients with chronic hepatitis B virus infection.
    J Hepatol. 2017 Jun 21. pii: S0168-8278(17)32081.
    PubMed     Text format    


  212. POORDAD F, Nelson DR, Feld JJ, Fried MW, et al
    Safety of the 2D/3D direct acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - a pooled analysis.
    J Hepatol. 2017 Jun 20. pii: S0168-8278(17)32083.
    PubMed     Text format     Abstract available


  213. CHAYANUPATKUL M, Kanwal F
    Author's reply to "Hepatocellular carcinoma (HCC) in the absence of cirrhosis in patients with chronic hepatitis B virus infection".
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32075.
    PubMed     Text format    


  214. PANG Q, Liu HC, Zhou L, Jin H, et al
    Inappropriateuse of FIB-4 index for cirrhosis detection in hepatocellular carcinoma patients.
    J Hepatol. 2017 Jun 18. pii: S0168-8278(17)32082.
    PubMed     Text format    


  215. NAGATA H, Nakagawa M, Asahina Y, Sato A, et al
    Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
    J Hepatol. 2017 Jun 13. pii: S0168-8278(17)32070.
    PubMed     Text format     Abstract available


  216. SUSSER S, Dietz J, Schlevogt B, Zuckerman E, et al
    Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras.
    J Hepatol. 2017 Jun 12. pii: S0168-8278(17)32069.
    PubMed     Text format     Abstract available


  217. DURIEZ M, Mandouri Y, Lekbaby B, Wang H, et al
    Alternative splicing of Hepatitis B virus: a novel virus/host interaction altering liver immunity.
    J Hepatol. 2017 Jun 6. pii: S0168-8278(17)32065.
    PubMed     Text format     Abstract available


    May 2017
  218. PEMBROKE T, Deschenes M, Lebouche B, Benmassaoud A, et al
    Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32047.
    PubMed     Text format     Abstract available


  219. ANDREASSON K, Waldenstrom J, Westin J, Norrgren H, et al
    JHEPAT-D-17-00297 R1: Cartilage oligomeric matrix protein associates with hepatic inflammation and fibrosis in hepatitis C virus infection.
    J Hepatol. 2017 May 17. pii: S0168-8278(17)32044.
    PubMed     Text format    


  220. TAN-GARCIA A, Wai LE, Zheng D, Ceccarello E, et al
    Intrahepatic CD206+ macrophages contribute to inflammation in advanced viral-related liver disease.
    J Hepatol. 2017 May 5. pii: S0168-8278(17)32004.
    PubMed     Text format     Abstract available


  221. COLPITTS CC, Baumert TF
    SCARB1 variants and HCV infection: Host susceptibility is lost in translation.
    J Hepatol. 2017 May 3. pii: S0168-8278(17)30255.
    PubMed     Text format    


  222. WENDON, J, Cordoba J, Dhawan A, Larsen FS, et al
    EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure.
    J Hepatol. 2017;66:1047-1081.
    PubMed     Text format     Abstract available


  223. MRIDHA AR, Wree A, Robertson AAB, Yeh MM, et al
    NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
    J Hepatol. 2017;66:1037-1046.
    PubMed     Text format     Abstract available


    April 2017
  224. BANKWITZ D, Doepke M, Hueging K, Weller R, et al
    Maturation of secreted HCV particles by incorporation of secreted apoE protects from antibodies by enhancing infectivity.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30251.
    PubMed     Text format     Abstract available


  225. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection.
    J Hepatol. 2017 Apr 21. pii: S0168-8278(17)30249.
    PubMed     Text format     Abstract available


  226. BRUNO S, Maisonneuve P
    Response to the letter regarding the manuscript "Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population".
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30216.
    PubMed     Text format    


  227. HALLAGER S, Ladelund S, Weis N
    Methodological considerations when calculating person time at risk for patients with chronic hepatitis C undergoing antiviral treatment.
    J Hepatol. 2017 Apr 20. pii: S0168-8278(17)30218.
    PubMed     Text format    


  228. LOUVET A, Peck-Radosavljevic M
    Evidence for a role of genetics in alcoholic hepatitis: data from the STOPAH randomized controlled trial.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30210.
    PubMed     Text format    


  229. LENGGENHAGER D, Gouttenoire J, Malehmir M, Bawohl M, et al
    Visualization of hepatitis E virus RNA and proteins in the human liver.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30212.
    PubMed     Text format     Abstract available


  230. KWO PY, Poordad F, Asatryan A, Wang S, et al
    Glecaprevir and Pibrentasvir Yield High response Rates in Patients with HCV Genotype 1-6 without Cirrhosis.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30211.
    PubMed     Text format     Abstract available


  231. THONS C, Senff T, Hydes TJ, Manser AR, et al
    HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30213.
    PubMed     Text format     Abstract available


  232. VAN SANTEN DK, Van Der Helm JJ, Del Amo J, Meyer L, et al
    Lack of decline in Hepatitis C Virus incidence among HIV-positive men who have sex with men during 1990-2014.
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30209.
    PubMed     Text format     Abstract available


  233. ZIMMERMANN R, Kollan C, Ingiliz P, Mauss S, et al
    Reply to "Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030".
    J Hepatol. 2017 Apr 12. pii: S0168-8278(17)30204.
    PubMed     Text format    


  234. DORE GJ, Grebely J
    Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30206.
    PubMed     Text format    


  235. TUMINO N, Casetti R, Fabbri G, Cimini E, et al
    In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30207.
    PubMed     Text format    


  236. HASSON H, Merli M, Messina E, Bhoori S, et al
    Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals.
    J Hepatol. 2017 Apr 11. pii: S0168-8278(17)30203.
    PubMed     Text format     Abstract available


  237. LANGHANS B
    Reply to "In HIV/HCV co-infected patients T regulatory and myeloid derived suppressor cells persist after successful treatment with directly acting antivirals".
    J Hepatol. 2017 Apr 9. pii: S0168-8278(17)30205.
    PubMed     Text format    


  238. SCHWARZINGER M, Baillot S, Yazdanpanah PY, Rehm PJ, et al
    Contribution of Alcohol Use Disorders on the Burden of Chronic Hepatitis C in France, 2008-2013: A Nationwide Retrospective Cohort Study.
    J Hepatol. 2017 Apr 7. pii: S0168-8278(17)30202.
    PubMed     Text format     Abstract available


  239. SHIRVANI-DASTGERDI E, Winer BY, Celia-Terrassa A, Kang Y, et al
    Selection of the highly replicative and partially multidrug resistant rtS78T polymerase mutation in two patients with chronic hepatitis B virus infection during tenofovir-entecavir combination therapy.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30198.
    PubMed     Text format     Abstract available


  240. TAPPER EB, Sengupta N
    Testing for elevated liver enzymes: central to clinical Hepatology but in need of more data.
    J Hepatol. 2017 Apr 6. pii: S0168-8278(17)30199.
    PubMed     Text format    


  241. YU X, Lan P, Hou X, Han Q, et al
    HBV inhibits LPS-induced NLRP3 inflammasome activation and IL-1beta production via suppressing the NF-kappaB pathway and ROS production.
    J Hepatol. 2017;66:693-702.
    PubMed     Text format     Abstract available


  242. MOHS A, Kuttkat N, Reissing J, Zimmermann HW, et al
    Functional role of CCL5/RANTES for HCC progression during chronic liver disease.
    J Hepatol. 2017;66:743-753.
    PubMed     Text format     Abstract available


    March 2017
  243. WESTHAUS S, Deest M, Nguyen AT, Stanke F, et al
    Scavenger receptor class B member 1 (SCARB1) variants modulate hepatitis C virus replication cycle and viral load.
    J Hepatol. 2017 Mar 28. pii: S0168-8278(17)30184.
    PubMed     Text format     Abstract available



  244. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
    J Hepatol. 2017 Mar 27. pii: S0168-8278(17)30185.
    PubMed     Text format     Abstract available


  245. WELZEL T, Bhardwaj N, Hedskog C, Chodavarapu K, et al
    Global Epidemiology of HCV Subtypes and Resistance-associated Substitutions Evaluated by Sequencing-Based Subtype Analyses.
    J Hepatol. 2017 Mar 23. pii: S0168-8278(17)30148.
    PubMed     Text format     Abstract available


  246. BERTUCCIO P, Turati F, Carioli G, Rodriguez T, et al
    Global Trends and Predictions in Hepatocellular Carcinoma Mortality.
    J Hepatol. 2017 Mar 20. pii: S0168-8278(17)30145.
    PubMed     Text format     Abstract available


  247. BELLI LS, Duvoux C, Berg T, Strazzabosco M, et al
    ELITA consensus statements on use of DAAs in liver transplant candidates and recipients.
    J Hepatol. 2017 Mar 18. pii: S0168-8278(17)30140.
    PubMed     Text format     Abstract available


  248. MARTIN NK, Vickerman P, Hickman M
    How to eliminate HCV infection by antiviral treatment.
    J Hepatol. 2017 Mar 17. pii: S0168-8278(17)30142.
    PubMed     Text format    


  249. BRUNETTO M, Cornberg M, Chan HL
    How Good Is Hepatitis B Surface Antigen Kinetics Informing Strategy to Stop Antiviral Therapy?
    J Hepatol. 2017 Mar 15. pii: S0168-8278(17)30136.
    PubMed     Text format    


  250. TACKE F
    Targeting hepatic macrophages to treat liver diseases.
    J Hepatol. 2017 Mar 3. pii: S0168-8278(17)30125.
    PubMed     Text format     Abstract available


    February 2017
  251. RAMOS-CASALS M, Zignego AL, Ferri C, Brito-Zeron P, et al
    Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection.
    J Hepatol. 2017 Feb 17. pii: S0168-8278(17)30105.
    PubMed     Text format     Abstract available


  252. GREBELY J, Swan T, Hickman M, Bruneau J, et al
    Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30054.
    PubMed     Text format    


  253. PAWLOTSKY JM
    Consistent advice for people who inject drugs in the 2016 EASL Recommendations on treatment of hepatitis C.
    J Hepatol. 2017 Feb 3. pii: S0168-8278(17)30055.
    PubMed     Text format    


    January 2017
  254. KLAG T, Dietz J, Werner CR, Schwarz JM, et al
    Hepatitis C "true" late relapse beyond 48 weeks of sustained virologic response after direct acting antiviral therapy.
    J Hepatol. 2017 Jan 9. pii: S0168-8278(17)30006.
    PubMed     Text format    


  255. OTT JJ, Horn J, Krause G, Mikolajczyk RT, et al
    Time trends of chronic HBV infection over prior decades - A global analysis.
    J Hepatol. 2017;66:48-54.
    PubMed     Text format     Abstract available


    December 2016
  256. VUKOTIC R, Conti F, Andreone P
    Hepatitis C virus eradication in elderly: The challenge worth a long-life elixir?
    J Hepatol. 2016 Dec 21. pii: S0168-8278(16)30745.
    PubMed     Text format    


    November 2016
  257. HELLARD M, Pedrana A, Scott N
    Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
    J Hepatol. 2016 Nov 21. pii: S0168-8278(16)30680.
    PubMed     Text format    


  258. TSAI PC, Huang CF, Yu ML
    Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: issue of tie interval between HCC treatment and antiviral therapy.
    J Hepatol. 2016 Nov 10. pii: S0168-8278(16)30646.
    PubMed     Text format    


  259. FALADE-NWULIA O, Sulkowski M
    The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection.
    J Hepatol. 2016 Nov 2. pii: S0168-8278(16)30636.
    PubMed     Text format    


    October 2016
  260. ROSS DB, Belperio PS, Chartier M, Backus LI, et al
    Hepatitis C Testing in U.S. Veterans Born 1945-1965: An Update.
    J Hepatol. 2016 Oct 5. pii: S0168-8278(16)30557.
    PubMed     Text format    


  261. JUSTICE AC, Esserman D, Sarkar S, Levin FL, et al
    Reply to: "Disparities in Hepatitis C Testing in U.S. Veterans Born 1945-1965".
    J Hepatol. 2016 Oct 4. pii: S0168-8278(16)30558.
    PubMed     Text format    


  262. FORNS X, Berg T
    Hepatitis C virus - A teacher of clinical research, cell biology and immunology.
    J Hepatol. 2016;65.
    PubMed     Text format    


    September 2016

  263. EASL Recommendations on Treatment of Hepatitis C 2016.
    J Hepatol. 2016 Sep 12. pii: S0168-8278(16)30489.
    PubMed     Text format    


    July 2016
  264. BENECHET AP, Iannacone M
    Determinants of hepatic effector CD8+ T cell dynamics.
    J Hepatol. 2016 Jul 13. pii: S0168-8278(16)30335.
    PubMed     Text format     Abstract available


  265. NAULT JC, Colombo M
    Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.
    J Hepatol. 2016 Jul 11. pii: S0168-8278(16)30327.
    PubMed     Text format    


    May 2016
  266. BILLERBECK E, Mommersteeg MC, Shlomai A, Xiao JW, et al
    Humanized mice efficiently engrafted with fetal hepatoblasts and syngeneic immune cells develop human monocytes and NK cells.
    J Hepatol. 2016 May 2. pii: S0168-8278(16)30166.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: